Allogeneic hematopoietic stem cell transplantation in Primary Cutaneous T Cell Lymphoma
Authors:
- Laura CudilloLCLaura Cudillo
- William Arcese For The Rome Transplant NetworkWNWilliam Arcese For The Rome Transplant Network
- Raffaella CerrettiRCRaffaella Cerretti
- Alessandra PicardiAPAlessandra Picardi
- Benedetta MariottiBMBenedetta Mariotti
- Maria CantonettiMCMaria Cantonetti
- Massimiliano PostorinoMPMassimiliano Postorino
- Eleonora CeresoliECEleonora Ceresoli
- Daniela NassoDNDaniela Nasso
- Francesco PisaniFPFrancesco Pisani
- 13 February 2018
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 97 (6) , 1041-1048
Abstract
In our retrospective study, 16 patients affected by advanced cutaneous T cell lymphoma (CTCL) underwent allogeneic hematopoietic stem cell transplantation (HSCT). Two patients (12.5%) were in complete remission (CR), nine (56.3%) in partial remission (PR), and five (31.2%) with active disease. The patients were transplanted from an HLA-identical (n = 7) from a mismatched (n = 1) or haploidentical (n = 1) sibling, from matched unrelated donor (n = 5), or from a single cord blood unit (n = 2). Conditioning regimen was standard myeloablative in 6 patients and at reduced intensity in 10. Seven patients died from non relapse mortality (NRM) and four patients relapsed or progressed, three of them achieved a second CR after donor lymphocyte infusion (DLI) or chemotherapy plus DLI. To date, with a median follow-up of 76 months (range 6–130), nine patients are alive, eight in CR, and one with active disease. Overall survival (OS) and disease-free survival (DFS) at 1 and 10 years are 61% (95% CI 40–91%) and 54% (95% CI 33–86%), 40% (95% CI 22–74%), and 34% (95% CI 16–68%), respectively. The time from diagnosis to transplant seems to influence negatively both OS (log-rank p < 0.04) and DFS (log-rank p < 0.05). Our results confirm on a long follow-up that CTCL appears particularly susceptible to the graft versus lymphoma (GVL) effect, so that allogeneic HSCT represents a possibility of cure for advanced CTCL. The timing of HSCT in the clinical course of disease remains an open issue.Keywords
This publication has 27 references indexed in Scilit:
- How I treat mycosis fungoides and Sézary syndromeBlood, 2016
- Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)Journal of the American Academy of Dermatology, 2014
- Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome)Journal of the American Academy of Dermatology, 2014
- Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- Non–Mycosis Fungoides Cutaneous T-Cell LymphomasAmerican Journal of Clinical Pathology, 2013
- Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 casesBlood, 2009
- Review of the Treatment of Mycosis Fungoides and Sézary Syndrome: A Stage-Based ApproachJournal of the National Comprehensive Cancer Network, 2008
- Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)Blood, 2007
- TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC)Blood, 2007
- WHO-EORTC classification for cutaneous lymphomasBlood, 2005